PD-1/PD-L1 inhibitors respectively bind to PD-1 or PD-L1 to prevent the interaction between PD-1 and PD-L1, then the recognition and killing effect of immune cells is restored and the immune escape of tumor cells is avoided (Figure 1). The gene discussed is PDCD1; the disease is neoplasm.